1. Canceled

2. Canceled

3. Canceled

4. Canceled

5. Canceled

6. Canceled

7. Canceled

8. Canceled

9. Canceled

10. Canceled

11. Canceled

12. Canceled

13. Canceled

14. Canceled

15. Canceled

16. Canceled

17. Canceled

18. Canceled

19. Canceled

20. Canceled

21. Canceled

22. Canceled

23. Canceled

24. Canceled

25. Canceled

26. Canceled

27. Canceled

28. Canceled

29. Canceled

30. Canceled

31. Canceled

32. Canceled

33. Canceled

34. Canceled

35. Canceled

36. (currently amended) A method for the treatment of a disease condition in a mammal, which condition means the presence of specific cells that are associated with the condition by the expression of a disease specific cell surface structure, wherein one administers to the mammal a therapeutically effective amount of covalent conjugate that is able to activate T lymphocytes to lyse cells that carry the disease specific cell surface structure and comprises:

a. a biospecific affinity counterpart that is capable of binding to said surface structure, and

b. a peptide that

i. contains an amino acid sequence that is derived from a superantigen selected from the group consisting of staphylococcal enterotoxin A, B, C1, C2, D and E,

ii. has the ability to bind to a Vβ of a T cell receptor, and

iii. has been mutated <u>in that at least one of the following amino acid residue substitutions have been made: F47A, N128A, H187A, H225A or D227A in staphylococcal enterotoxin A or corresponding residues in the other superantigens</u> to show a modified ability to bind to MHC class II antigens compared to the superantigens from which the peptide is derived.

37. Canceled

38. Canceled

39. Canceled

40. Canceled

41. Canceled

42. Canceled

43. Canceled

44. Canceled

45. Canceled

46. Canceled

47. Canceled

48. Canceled

49. Canceled

50. Canceled

51. Canceled

52. Canceled

53. Withdrawn

54. Withdrawn

55. Withdrawn

56. Withdrawn

57. Withdrawn

58. (new) The method of claim 36, wherein the disease is selected from the group consisting of cancer, viral infection, autoimmune disease and parasitic infestation.

59. (new) The method of claim 58, wherein the disease is cancer.

60. (new) The method of claim 36, wherein the biospecific affinity counterpart comprises polypeptide structure.

61. (new) The method of claim 60, wherein the biospecific affinity counterpart is selected from the group consisting of an antibody or an antigen-binding fragment thereof.

62. (new) The method of claim 60, wherein the biospecific counterpart and the peptide are fused together.

63. (new) The method of claim 61, wherein the biospecific counterpart and the peptide are fused together.

64. (new) The method of claim 36, wherein the superantigen is staphylococcal enterotoxin A.